Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13413651 | 0.85 | MAPT (0.54) | RECQLMAPTTBXAS1KAT2BLMNA | |
| SCHEMBL10421950 | 0.80 | MAPT (0.56) | RECQLMAPTTBXAS1LMNASMN1; SMN2 | |
| SCHEMBL10485351 | 0.77 | PKM (0.55) | RECQLMAPTKAT2BLMNASMN1; SMN2 | |
| SCHEMBL12877767 | 0.76 | LMNA (0.64) | RECQLMAPTTBXAS1LMNASMN1; SMN2 | |
| SCHEMBL3316327 | 0.76 | KAT2B (0.52) | MAPTKAT2BLMNASMN1; SMN2GAA | |
| SCHEMBL24000681 | 0.76 | MAPT (0.48) | RECQLMAPTTBXAS1KAT2BKMT2A | |
| SCHEMBL13829800 | 0.75 | MAPT (0.60) | RECQLMAPTTBXAS1KAT2BLMNA | |
| SCHEMBL13728276 | 0.75 | MAPT (0.56) | RECQLMAPTTBXAS1KAT2BLMNA | |
| SCHEMBL3312575 | 0.74 | CNR2 (0.51) | MAPTKAT2BSMN1; SMN2KMT2A | |
| SCHEMBL3319604 | 0.74 | CNR2 (0.51) | MAPTKAT2BSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278098-B2 | Substituted phthalazines for inducing insulin secretion and protecting beta-cells | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2015-06-18 | — | — | US | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2132183-B1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | Univ Virginia Patent Found (US) | 2015-06-03 | — | — | EP | disclosed |
| US-8871764-B2 | Lisofylline analogs and methods for use | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-04-29 | — | — | US | disclosed |
| EP-2132183-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | University Of Virginia Patent Foundation (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008108842-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150164892-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | RECQL 938/4885MAPT 4048/4885TBXAS1 1911/4885 |
| US-20100105690-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | RECQL 1030/4885MAPT 3953/4885TBXAS1 2104/4885 |
| US-20130137693-A1 | LISOFYLLINE ANALOGS AND METHODS FOR USE | IAPP, RNASE1, CTSA | RECQL 1030/4885MAPT 3953/4885TBXAS1 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.